A H3K27M-targeted vaccine in adults with diffuse midline glioma.

Authors:
Grassl N; Poschke I; Lindner K; Bunse L; Mildenberger I and 21 more

Journal:
Nat Med

Publication Year: 2023

DOI:
10.1038/s41591-023-02555-6

PMCID:
PMC10579055

PMID:
37735561

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Nat Med

Abbreviation: Nat Med

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Molecular Biology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A candidate antibody drug for prevention of malaria.
Williams KL; Guerrero S; Flores-Garcia Y and 27 more (2024) - Transparency Score: 5/6
A deep learning system for predicting time to progression of diabetic retinopathy.
Dai L; Sheng B; Sheng B and 50 more (2024) - Transparency Score: 5/6
Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized…
Weitz JI; Tankó LB; Floege J and 8 more (2024) - Transparency Score: 3/6
Antimalarial artesunate-mefloquine versus praziquantel in African children with schistosomiasis: an…
Bottieau E; Mbow M; Brosius I and 17 more (2024) - Transparency Score: 5/6
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 tr…
Trudel S; McCurdy A; Louzada ML and 10 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests M.P. and E.W.G. are founders of Tcelltech and inventors of associated intellectual property related to glioma-reactive T cell receptors (patent no. WO2022200456A1). M.P. and W.W. are inventors of associated intellectual property related to IDH1R132H vaccine (patent nos. EP2800580B1 and US10161940B2). M.P., K.S. and L.B. are inventors of associated intellectual property related to H3K27M vaccines (patent nos. EP3118217A1 and US20180155403A1). U.H. received speakers and/or advisory board honoraria from Medac, Janssen and Bayer. The remaining authors declare no competing interests."

Evidence found in paper:

"Funding Open access funding provided by Deutsches Krebsforschungszentrum (DKFZ)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025